# NM_006302.3(MOGS):c.546G>A (p.Gly182=)

https://sugi.bio/variant/mogs-p-gly182

## Summary

**MOGS p.Gly182= (c.546G>A)** is classified **Likely benign** in MOGS (ClinVar, Single submitter, 1 submitter; last evaluated 2025-09-29). Very rare (popmax 0.00169%, nfe); Associated with MOGS-congenital disorder of glycosylation.

**At a glance:** Likely benign · review: Single submitter · rsID rs367819963 · 1 submitter · 1 linked condition · very rare (popmax 0.00169%, nfe)

## For patients & families {#patients}

This is a change in the MOGS gene that is classified as likely benign — not considered disease-causing, submitted by 1 submitter, and is linked to MOGS-congenital disorder of glycosylation.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

|  |  |
| --- | --- |
| Typical inheritance (of this condition) | Autosomal recessive |
| Age of onset (of this condition) | Infancy, Neonatal |
| Diagnostic panels | MOGS is a diagnostic-grade gene on 14 Genomics England panels |

**Commonly reported features of MOGS-CDG** (across patients with this condition; presentation varies — frequencies from Orphanet):

- Retrognathia — Frequent (79-30%)
- Wide nose — Frequent (79-30%)
- Long eyelashes — Frequent (79-30%)
- Hirsutism — Frequent (79-30%)
- Seizure — Frequent (79-30%)
- Abnormal facial shape — Frequent (79-30%)
- Decreased circulating IgA level — Frequent (79-30%)
- Decreased circulating total IgM — Frequent (79-30%)

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0010767/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [MOGS](https://sugi.bio/atlas/gene/MOGS/) |
| Protein change (HGVS p.) | p.Gly182= |
| Coding change (HGVS c.) | c.546G>A |
| MANE Select transcript | [NM_006302](https://www.ncbi.nlm.nih.gov/nuccore/NM_006302) |
| dbSNP | [rs367819963](https://www.ncbi.nlm.nih.gov/snp/rs367819963/) |
| Variant type | single nucleotide variant |
| Location | chr2:74464529-74464529 (GRCh38) |
| ClinVar | [VCV1544959](https://www.ncbi.nlm.nih.gov/clinvar/variation/1544959/) |

**All HGVS expressions:** `LRG_1226:g.5882G>A`, `LRG_1226t1:c.546G>A`, `NC_000002.11:g.74691656C>T`, `NC_000002.12:g.74464529C>T`, `NG_008922.1:g.5882G>A`, `NM_001146158.2:c.228G>A`, `NM_006302.3:c.546G>A`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation and, for splice-region changes, SpliceAI (below), not from a missing predictor score.
- SpliceAI predicts **donor gain** (Δ 0.27) — a splice-altering prediction the current classification does not reflect
- Conservation: phyloP 2.713, GERP 0.604, phastCons 1 — highly conserved position (PP3-type support)
- CADD: **PHRED 14.16**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI deltas (raw): acceptor loss **0.00**, donor loss **0.01**, acceptor gain **0.00**, donor gain **0.27**. Largest is donor gain.
- SpliceAI deltas (masked): acceptor loss **0.00**, donor loss **0.00**, acceptor gain **0.00**, donor gain **0.27**.
- Population frequency (gnomAD v4.1): grpmax **0.00169%** (nfe) · FAF95 0.00111% · FAF99 0.0009% · 20/1,180,014 in the highest group · 20/1,614,118 alleles overall — very rare (popmax 0.00169%, nfe).

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**MOGS** population constraint: LOEUF 0.85, pLI 2.6946e-10, missense-Z 0.86484. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **MOGS-congenital disorder of glycosylation** — Definitive (AR)

## Protein context {#protein}


AlphaFold model confidence (whole protein): pLDDT 92.42, 86% of residues very-high.

## What this gene does {#gene-function}

*Describes the biological roles of MOGS (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*

**How this variant is thought to act:** MOGS participates in disease-associated pathways. In Reactome, MOGS is annotated in disease pathway(s) including **Defective MOGS causes CDG-2b**, **Maturation of spike protein**.

**Disease mechanism (Reactome):** MOGS loss or alteration is curated in [Defective MOGS causes CDG-2b](https://reactome.org/content/detail/R-HSA-4793954), [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9683686), [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9694548).

### Pathways affected {#pathways}

MOGS participates in **5 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| ⚕ [Defective MOGS causes CDG-2b](https://reactome.org/content/detail/R-HSA-4793954) | curated |
| ⚕ [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9683686) | curated |
| ⚕ [Maturation of spike protein](https://reactome.org/content/detail/R-HSA-9694548) | curated |
| [N-glycan trimming in the ER and Calnexin/Calreticulin cycle](https://reactome.org/content/detail/R-HSA-532668) | curated |
| [Regulation of CDH1 posttranslational processing and trafficking to plasma membrane](https://reactome.org/content/detail/R-HSA-9768727) | curated |

## Clinical significance {#significance}

**Likely benign** — review status Single submitter *(criteria provided, single submitter)*, last evaluated 2025-09-29.

**Submitter consensus:** unanimous (1/1 Likely benign).

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Labcorp Genetics (formerly Invitae), Labcorp | Likely benign | criteria provided, single submitter | clinical testing | 2025-09-29 |

## Associated conditions {#conditions}

[MOGS-congenital disorder of glycosylation](https://sugi.bio/atlas/disease/mogs-congenital-disorder-of-glycosylation/).

**Reported phenotype names (ClinVar):** MOGS-congenital disorder of glycosylation, GLUCOSIDASE I DEFICIENCY, CDG IIb, CDG 2B, MOGS-CDG.

## Similar variants {#similar}

Related MOGS variant pages (same residue, condition, or type): [MOGS p.Arg495Ter](/variant/mogs-p-arg495ter), [MOGS p.Gln124Ter](/variant/mogs-p-gln124ter), [MOGS p.Gln505Ter](/variant/mogs-p-gln505ter), [MOGS p.Ala22Glu](/variant/mogs-p-ala22glu), [MOGS p.Ala292Asp](/variant/mogs-p-ala292asp), [MOGS p.Ala292Pro](/variant/mogs-p-ala292pro), [MOGS p.Ala41Val](/variant/mogs-p-ala41val), [MOGS p.Ala510Thr](/variant/mogs-p-ala510thr).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-14); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 1544959). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*